S

Sanofi

Global pharma company; vaccines and R&D

People Business Partner Research and Development North America

Full-TimeUpdated on 10/23/2026Deadline 10/29/26
$225k - $325k
Expert
Bachelor's
Cambridge, MA, USA+1 moreMore locations: Morristown, NJ, USA
HybridHybrid role; listed ATS workplaces are Cambridge, MA and Morristown, NJ.
People & HRHR Generalist & Employee Relations

About the job

Requirements
  • A university degree in Business Administration, HR Management, Labor Law, Psychology, or a comparable field.
  • Fluency in English.
  • 10–15 years of professional People & Culture experience.
  • Strong experience with common People management processes, including performance and reward, talent acquisition, development, and succession planning, and related digital tools.
  • Strong business orientation and commercial-mindedness.
  • Ability to act within a globally integrated operating model and work seamlessly with global and local leadership teams.
  • Ability to scope, plan, and implement People & Culture projects, including appropriate change-management support.
  • Experience in organizational design and development, such as Space to Lead.
  • Knowledge of U.S. labor law.
  • Structured and independent thinking and working, ability to work in a team, self- and situational awareness, ability to manage by influence, flexibility, and resilience.
Responsibilities
  • Drive the talent agenda with business leaders in scope, establishing talent reviews and high-quality succession plans for roles up to and including L5 for overall R&D across North America.
  • Advise and guide North America-based R&D teams on executing the R&D business strategy in alignment with global business partners of the corresponding R&D functions and Sanofi North America People & Culture, as necessary.
  • Manage communication and execution of organizational initiatives and individual employee-relations issues, with support from People Excellence, People Services, and Legal functions as necessary.
  • Bring the People & Culture agenda to life by advising, coaching, and influencing business leadership teams across client groups in scope.
  • Contribute to global operational and strategic workforce planning for R&D by providing the country perspective for all departments in scope.
  • Drive and support delivery of R&D People priorities in North America and coordinate in-country projects.
  • Hold managers accountable for leading and developing their people through key development activities and use of available online tools and resources.
  • Leverage local people insights to drive local initiatives and projects and provide the voice of the customer for global initiatives.
  • Promote Sanofi diversity, equity, and inclusion and culture through in-country initiatives, incorporating legal and local cultural perspectives.
  • Manage complex cases by exception.
  • Proactively encourage managers and employees to use available self-service tools and OneSupport.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...